NEETASOMAIAHNEETA SOMAIAH9847SOMAIAH, NEETAAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1815522Authorship 1894681Authorship 1928272Authorship 1937672Authorship 195088819029251Banumathy G, Somaiah N, Zhang R, Tang Y, Hoffmann J, Andrake M, Ceulemans H, Schultz D, Marmorstein R, Adams PDMolecular and cellular biologyHuman UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol Cell Biol. 2009 Feb; 29(3):758-70.Mol Cell Biol2008-11-24T00:00:002008Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells.22005529Somaiah N, Simon GRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMolecular targeted agents and biologic therapies for lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1758-85.J Thorac Oncol2011-11-01T00:00:002011Molecular targeted agents and biologic therapies for lung cancer.24117526Al-Zaid T, Somaiah N, Lazar AJHistopathologyTargeted therapies for sarcomas: new roles for the pathologist. Histopathology. 2014 Jan; 64(1):119-33.Histopathology2013-12-02T00:00:002013Targeted therapies for sarcomas: new roles for the pathologist.24377743Simon GR, Somaiah NClinical lung cancerA tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer. 2014 Jan; 15(1):21-51.Clin Lung Cancer2013-11-21T00:00:002013A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.24448245Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li SCancer researchUniversal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014 Mar 15; 74(6):1645-50.Cancer Res2014-01-21T00:00:002014Universal marker and detection tool for human sarcoma circulating tumor cells.LeukemiaSarcoma Medical OncologySurgical OncologyThoracic Head & Neck Medical OncologyMD AndersonJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorANTHONY PAULCONLEYANTHONY PAUL CONLEY9418CONLEY, ANTHONY PAULAssistant ProfessorGEORGESIMONGEORGE SIMON9820SIMON, GEORGEProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessor3.991470.00925121295research areas3.289810.030858188coauthor of115.48818.500160similar to11116selected publicationsSHREYASKUMARPATELSHREYASKUMAR PATEL8514PATEL, SHREYASKUMARProfessorALEXANDERLAZARALEXANDER LAZAR9206LAZAR, ALEXANDERProfessorVINODRAVIVINOD RAVI9533RAVI, VINODAssociate ProfessorCHRISTINA LYNNROLANDCHRISTINA LYNN ROLAND9744ROLAND, CHRISTINA LYNNAssistant ProfessorAuthorship 2267391Authorship 2288891Authorship 2291093Authorship 2295462Authorship 2320382Authorship 234302519248977Somaiah N, von Mehren MHematology/oncology clinics of North AmericaNew therapeutic approaches for advanced gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009 Feb; 23(1):139-50, x.Hematol Oncol Clin North Am2009-02-01T00:00:002009New therapeutic approaches for advanced gastrointestinal stromal tumors.20679541Aggarwal C, Somaiah N, Simon GRJournal of the National Comprehensive Cancer Network : JNCCNBiomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw. 2010 Jul; 8(7):822-32.J Natl Compr Canc Netw2010-07-01T00:00:002010Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?21102235Somaiah N, Simon GRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMolecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S434-54.J Thorac Oncol2010-12-01T00:00:002010Molecular targeted agents and biologic therapies for non-small cell lung cancer.21178721Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan RJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerSummary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). J Thorac Oncol. 2011 Jan; 6(1):227-32.J Thorac Oncol2011-01-01T00:00:002011Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010).22481432Aggarwal C, Somaiah N, Simon GCancer biology & therapyAntiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012 Mar; 13(5):247-63.Cancer Biol Ther2012-03-01T00:00:002012Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?24357742Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GRCancer control : journal of the Moffitt Cancer CenterMultidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. Cancer Control. 2014 Jan; 21(1):57-62.Cancer Control2014-01-01T00:00:002014Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery.Authorship 2543661Authorship 2587451Authorship 2589081Authorship 261221219861914Somaiah N, Simon GRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMolecular targeted therapy in non-small cell lung cancer: an overview of available agents. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1046-56.J Thorac Oncol2009-11-01T00:00:002009Molecular targeted therapy in non-small cell lung cancer: an overview of available agents.23160320Somaiah N, Simon NG, Simon GRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S342-68.J Thorac Oncol2012-12-01T00:00:002012A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.23226072Somaiah N, von Mehren MCancer management and researchNew drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res. 2012; 4:397-411.Cancer Manag Res2012-11-23T00:00:002012New drugs and combinations for the treatment of soft-tissue sarcoma: a review.24216990Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RECancersNovel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel). 2013 May 10; 5(2):529-49.Cancers (Basel)2013-05-10T00:00:002013Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results.Authorship 2677584Authorship 2695392217242198Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PDMolecular and cellular biologyDefinition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol. 2007 Apr; 27(7):2452-65.Mol Cell Biol2007-01-22T00:00:002007Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci.20581300Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW, National Comprehensive Cancer Network Bone Cancer PanelJournal of the National Comprehensive Cancer Network : JNCCNBone cancer. J Natl Compr Canc Netw. 2010 Jun; 8(6):688-712.J Natl Compr Canc Netw2010-06-01T00:00:002010Bone cancer.Authorship 2799024Authorship 2894592Authorship 2923813Authorship 2929457Authorship 29332317Authorship 2936581Authorship 2941582Authorship 294512824840526Burgoyne AM, Somaiah N, Sicklick JKCurrent opinion in oncologyGastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol. 2014 Jul; 26(4):408-14.Curr Opin Oncol2014-07-01T00:00:002014Gastrointestinal stromal tumors in the setting of multiple tumor syndromes.25354575Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig BAnnals of surgical oncologyAccuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes. Ann Surg Oncol. 2015 Apr; 22(4):1068-72.Ann Surg Oncol2014-10-30T00:00:002014Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes.25412843Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bov?e JV, Lazar AJ, Nielsen TOModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncNY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015 Apr; 28(4):587-95.Mod Pathol2014-11-21T00:00:002014NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.25535693Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan RJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMolecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.J Thorac Oncol2015-01-01T00:00:002015Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.25594059Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GROncoscienceEpidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014; 1(8):522-528.Oncoscience2014-08-07T00:00:002014Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.25625925Tseng WW, Somaiah N, Engleman EGHuman vaccines & immunotherapeuticsPotential for immunotherapy in soft tissue sarcoma. Hum Vaccin Immunother. 2014; 10(11):3117-24.Hum Vaccin Immunother2014-01-01T00:00:002014Potential for immunotherapy in soft tissue sarcoma.25705114Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Liz?e G, Radvanyi L, Hwu PSarcomaAnalysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma. 2015; 2015:547460.Sarcoma2015-01-29T00:00:002015Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.74Professor10Assistant Professor14Associate ProfessorAuthorship 841469Authorship 848115Authorship 850305Authorship 851421Authorship 854548Authorship 858893Authorship 860407SarcomaAnalysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma. 2015.Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal LiposarcomaJournal of Computer Assisted TomographyCan Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. Journal of Computer Assisted Tomography. Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?OncoscienceEpidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 1:522-528.Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lungSoft Tissue Sarcomas. 696-703.Soft Tissue SarcomasAmerican Journal of Clinical Oncology: Cancer Clinical TrialsPhase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ MalignanciesCurrent Oncology ReportsAn Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Current Oncology Reports. 18.An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST PatientsLaboratory InvestigationEstablishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Laboratory Investigation. 96:885-894.Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocationD012509Disorders49417100.465042SarcomaD046152Disorders1212960.783201Gastrointestinal Stromal TumorsD018234Disorders45750.910013Sarcoma, Alveolar Soft PartD008080Disorders722140.836887LiposarcomaAuthorship 9023398Authorship 9048009Authorship 90778612Authorship 9082586Authorship 9147503Authorship 9148306Authorship 91575716Authorship 91841315Authorship 9185306Authorship 91862411Authorship 9187765Authorship 9188637Authorship 9189338Authorship 91937213Authorship 9198854Authorship 9210992Authorship 9221324Authorship 9226629Authorship 9235743Authorship 9236448Authorship 92477412Authorship 9269455Authorship 92740611Authorship 9275013Authorship 9288048Authorship 9292974Authorship 9295171Authorship 9295886Authorship 9307488Authorship 93281814Authorship 9328619Authorship 9352774Authorship 936652225503432Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn LAmerican journal of clinical oncologyPhase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130. Am J Clin Oncol. 2017 Aug; 40(4):329-335.Am J Clin Oncol2017-08-01T00:00:002017Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.28284172Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs NEuropean journal of cancer (Oxford, England : 1990)Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour?patients. Eur J Cancer. 2017 05; 76:76-83.Eur J Cancer2017-03-08T00:00:002017Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour?patients.27454788Bhosale P, Wang J, Varma D, Jensen C, Patnana M, Wei W, Chauhan A, Feig B, Patel S, Somaiah N, Sagebiel TJournal of computer assisted tomographyCan Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma? J Comput Assist Tomogr. 2016 Nov/Dec; 40(6):872-879.J Comput Assist Tomogr2016-11-01T00:00:002016Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?27270875de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, ?man P, Torres KE, Lev D, Nielsen TO, Bov?e JV, Lazar AJ, Somaiah NLaboratory investigation; a journal of technical methods and pathologyEstablishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest. 2016 08; 96(8):885-94.Lab Invest2016-06-06T00:00:002016Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.27319943Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah NCurrent oncology reportsAn Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep. 2016 08; 18(8):49.Curr Oncol Rep2016-08-01T00:00:002016An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.28619757Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KKMolecular cancer therapeuticsCDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Mol Cancer Ther. 2017 09; 16(9):1751-1764.Mol Cancer Ther2017-06-15T00:00:002017CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.28424409Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah VOncotargetClinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.Oncotarget2017-06-13T00:00:002017Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.28654818de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bov?e JVMGTranslational oncologyHigh-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Transl Oncol. 2017 Aug; 10(4):546-554.Transl Oncol2017-06-24T00:00:002017High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.28664413Al-Zaid T, Wang WL, Somaiah N, Lazar AJVirchows Archiv : an international journal of pathologyMolecular profiling of sarcomas: new vistas for precision medicine. Virchows Arch. 2017 Aug; 471(2):243-255.Virchows Arch2017-06-29T00:00:002017Molecular profiling of sarcomas: new vistas for precision medicine.28652021Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Wang R, Li SCancer lettersDetection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett. 2017 09 10; 403:216-223.Cancer Lett2017-06-23T00:00:002017Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells.28240971Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DSJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Apr 20; 35(12):1304-1311.J Clin Oncol2017-02-27T00:00:002017Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.28842575Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah NScientific reportsTreatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep. 2017 08 25; 7(1):9519.Sci Rep2017-08-25T00:00:002017Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.29116489Goumard C, Marcal LP, Wang WL, Somaiah N, Okuno M, Roland CL, Tzeng CD, Chun YS, Feig BW, Vauthey JN, Conrad CAnnals of surgical oncologyLong-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. Ann Surg Oncol. 2018 Jan; 25(1):107-116.Ann Surg Oncol2017-11-07T00:00:002017Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases.28710342Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RSThe oncologistVincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.Oncologist2017-07-14T00:00:002017Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.28832986Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJCancerResults of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer. 2017 Dec 01; 123(23):4640-4647.Cancer2017-08-18T00:00:002017Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.29162825Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah VScientific reportsOutcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.Sci Rep2017-11-21T00:00:002017Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.28754721Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai AThe oncologistActivity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist. 2018 01; 23(1):62-70.Oncologist2017-07-28T00:00:002017Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.28822650Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu CThe Canadian journal of cardiologyProgressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol. 2017 10; 33(10):1335.e13-1335.e15.Can J Cardiol2017-06-08T00:00:002017Progressive and Reversible Conduction Disease With Checkpoint Inhibitors.28891906Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen JJournal of immunotherapy (Hagerstown, Md. : 1997)First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother. 2017 10; 40(8):302-306.J Immunother2017-10-01T00:00:002017First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.29081684Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah NSarcomaEarly Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma. 2017; 2017:7495914.Sarcoma2017-09-26T00:00:002017Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.29254498Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah VJournal for immunotherapy of cancerCharacteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.J Immunother Cancer2017-12-19T00:00:002017Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.29308306Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CLOncoimmunologyAnalysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689.Oncoimmunology2017-10-31T00:00:002017Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.29448300Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BWJournal of surgical oncologyIdentification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. 2018 Apr; 117(5):879-885.J Surg Oncol2018-02-15T00:00:002018Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy.29520652Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BWAnnals of surgical oncologySalvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. Ann Surg Oncol. 2018 Aug; 25(8):2193-2200.Ann Surg Oncol2018-03-08T00:00:002018Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit.29610390Beird HC, Wu CC, Ingram DR, Wang WL, Alimohamed A, Gumbs C, Little L, Song X, Feig BW, Roland CL, Zhang J, Benjamin RS, Hwu P, Lazar AJ, Futreal PA, Somaiah NCold Spring Harbor molecular case studiesGenomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud. 2018 04; 4(2).Cold Spring Harb Mol Case Stud2018-04-02T00:00:002018Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin.29228466Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BWJournal of surgical oncologyConcomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. J Surg Oncol. 2018 May; 117(6):1188-1194.J Surg Oncol2017-12-11T00:00:002017Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center.29721368Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li SOncoimmunologyCell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncoimmunology. 2018; 7(5):e1420450.Oncoimmunology2018-01-08T00:00:002018Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors.29731991Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong DOncotargetTargeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.Oncotarget2018-04-13T00:00:002018Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations.30237864Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DSOncotargetPrevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243.Oncotarget2018-09-04T00:00:002018Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.30241159Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SRJournal of global oncologyPositive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol. 2018 09; 4:1-6.J Glob Oncol2017-07-06T00:00:002017Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report.30249211Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CLBMC cancerPhase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913.BMC Cancer2018-09-24T00:00:002018Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.30032714Zobniw CM, Trinh VA, Posey K, Somaiah NJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersOlaratumab in the management of advanced soft tissue sarcoma. J Oncol Pharm Pract. 2019 Mar; 25(2):442-448.J Oncol Pharm Pract2018-07-22T00:00:002018Olaratumab in the management of advanced soft tissue sarcoma.30733229Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren EClinical cancer research : an official journal of the American Association for Cancer ResearchAlpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.Clin Cancer Res2019-02-07T00:00:002019Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.D012983Disorders3168820.581406Soft Tissue NeoplasmsPathologyAuthorship 9471251031096717Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik JCancersMAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).Cancers (Basel)2019-05-15T00:00:002019MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.Authorship 9497461Authorship 9500611131206726Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WLJournal of surgical oncologyThe degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol. 2019 Sep; 120(3):382-388.J Surg Oncol2019-06-17T00:00:002019The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum.31227504Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SMClinical cancer research : an official journal of the American Association for Cancer ResearchFirst-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.Clin Cancer Res2019-06-21T00:00:002019First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.Authorship 951076431268811Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WDJournal of oncology practiceIncidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 11; 15(11):e925-e933.J Oncol Pract2019-07-03T00:00:002019Incidence and Management of Olaratumab Infusion-Related Reactions.Authorship 9781801832081846Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PANature communicationsImmuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.Nat Commun2020-02-21T00:00:002020Immuno-genomic landscape of osteosarcoma.Authorship 979733932127467Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah VMolecular cancer therapeuticsGenomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.Mol Cancer Ther2020-03-03T00:00:002020Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.Authorship 988786232374488Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia SCancer medicineClinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 07; 9(13):4593-4602.Cancer Med2020-05-06T00:00:002020Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States.Authorship 989491432409969Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CLAnnals of surgical oncologyEvaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Ann Surg Oncol. 2021 Jan; 28(1):570-575.Ann Surg Oncol2020-05-14T00:00:002020Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum.Authorship 9924371932565716Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah NSarcomaPET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.Sarcoma2020-05-29T00:00:002020PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.Authorship 9973051032804590Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George SJournal of clinical oncology : official journal of the American Society of Clinical OncologySwitch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.J Clin Oncol2020-08-17T00:00:002020Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.Authorship 1005619133231866Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft ASCancerA randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.Cancer2020-11-24T00:00:002020A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.Authorship 1007256133312760Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SMOncoimmunologyA Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology. 2020 11 19; 9(1):1847846.Oncoimmunology2020-11-19T00:00:002020A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.Authorship 1011228733575859Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan RBreast cancer research and treatmentOutcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.Breast Cancer Res Treat2021-02-11T00:00:002021Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.Authorship 10128641233672607Kasper B, Achee A, Schuster K, Wilson R, van Oortmerssen G, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent JCancersUnmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (Basel). 2021 Feb 20; 13(4).Cancers (Basel)2021-02-20T00:00:002021Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).Authorship 10163571033855868Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia SFuture oncology (London, England)Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17(22):2923-2939.Future Oncol2021-04-15T00:00:002021Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Authorship 1019528434046772Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CLAnnals of surgical oncologyNational Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2021 Dec; 28(13):9159-9168.Ann Surg Oncol2021-05-27T00:00:002021National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors.Authorship 10262701134313371Zalcberg JR, Heinrich MC, George S, Bauer S, Sch?ffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JYThe oncologistClinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 11; 26(11):e2053-e2060.Oncologist2021-08-16T00:00:002021Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.Authorship 10277941134391056George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku FEuropean journal of cancer (Oxford, England : 1990)Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.Eur J Cancer2021-08-12T00:00:002021Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.Authorship 1031687234661454Symcox M, Somaiah NFuture oncology (London, England)Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study. Future Oncol. 2021 Dec 01; 17(36):5007-5012.Future Oncol2021-10-18T00:00:002021Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.Authorship 103949821Authorship 10407334Authorship 1041525235128664Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZInternational journal of cancerReal-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.Int J Cancer2022-02-18T00:00:002022Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center.35180772Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BAClinical cancer research : an official journal of the American Association for Cancer ResearchSystemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 09 15; 28(18):4092-4104.Clin Cancer Res2022-09-15T00:00:002022Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.35251319Thirasastr P, Somaiah NTherapeutic advances in medical oncologyOverview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. Ther Adv Med Oncol. 2022; 14:17588359221081073.Ther Adv Med Oncol2022-02-27T00:00:002022Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.Authorship 1043569335394800Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr?schel S, Hatcher H, Duffaud F, Herr?ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G?tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia SJournal of clinical oncology : official journal of the American Society of Clinical OncologySelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490.J Clin Oncol2022-04-08T00:00:002022Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.Authorship 1047006635647398Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJAdvances in radiation oncologyHypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol. 2022 May-Jun; 7(3):100913.Adv Radiat Oncol2022-02-05T00:00:002022Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions.Authorship 10481972Authorship 10481192835715139Thirasastr P, Brahmi M, Dufresne A, Somaiah N, Blay JYSurgical oncology clinics of North AmericaNew Drug Approvals for Sarcoma in the Last 5 Years. Surg Oncol Clin N Am. 2022 07; 31(3):361-380.Surg Oncol Clin N Am2022-07-01T00:00:002022New Drug Approvals for Sarcoma in the Last 5 Years.35705558Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DXNature communicationsClinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 06 15; 13(1):3406.Nat Commun2022-06-15T00:00:002022Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.Authorship 10500202135792683Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing ACancerClinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.Cancer2022-07-06T00:00:002022Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.Authorship 106068920Authorship 10598521Authorship 106007731Authorship 106208710Authorship 105966013Authorship 105490119Authorship 105654217Authorship 1058353936288393Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchExamining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.Clin Cancer Res2023-01-17T00:00:002023Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).35934010Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu PThe Lancet. OncologyDurvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.Lancet Oncol2022-08-04T00:00:002022Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.36343656Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJThe Lancet. OncologyHypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1547-1557.Lancet Oncol2022-11-04T00:00:002022Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.35943386Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley APJournal of immunotherapy (Hagerstown, Md. : 1997)Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 10 01; 45(8):374-378.J Immunother2022-08-04T00:00:002022Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.36151848Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah NCancer medicineRetrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.Cancer Med2022-09-24T00:00:002022Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.36313661Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EFFrontiers in oncologyThe immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.Front Oncol2022-10-12T00:00:002022The immune landscape of undifferentiated pleomorphic sarcoma.36603130Nguyen TDT, Wang Y, Bui TN, Lazcano R, Ingram DR, Yi M, Vakulabharanam V, Luo L, Pina MA, Karakas C, Li M, Kettner NM, Somaiah N, Hougton PJ, Mawlawi O, Lazar AJ, Hunt KK, Keyomarsi KCancer researchSequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.Cancer Res2023-03-15T00:00:002023Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time.35942596Thiebaud JA, Ravi V, Litwin S, Schuetze SM, Movva S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N, von Mehren MCancerOER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.Cancer2022-08-09T00:00:002022OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.Authorship 1064009236798653Thirasastr P, Somaiah NClinical and experimental gastroenterologyEmerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors. Clin Exp Gastroenterol. 2023; 16:11-19.Clin Exp Gastroenterol2023-02-10T00:00:002023Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.Authorship 10648567Authorship 1064900436853469Nassif EF, Keung EZ, Thirasastr P, Somaiah NCurrent treatment options in oncologyMyxoid Liposarcomas: Systemic Treatment Options. Curr Treat Options Oncol. 2023 04; 24(4):274-291.Curr Treat Options Oncol2023-02-28T00:00:002023Myxoid Liposarcomas: Systemic Treatment Options.36845725Nassif EF, Joseph CP, Lazcano R, Joseph JT, Thirasastr P, Lazar AJ, Somaiah NFrontiers in oncologyCase report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas. Front Oncol. 2023; 13:1046442.Front Oncol2023-02-09T00:00:002023Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas.Authorship 10656481436927527Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JVJournal for immunotherapy of cancerFirst-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer. 2023 03; 11(3).J Immunother Cancer2023-03-01T00:00:002023First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).Authorship 106764628Authorship 1067968437016732Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam FCancerPhase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.Cancer2023-04-04T00:00:002023Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.37058010Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.Clin Cancer Res2023-05-01T00:00:002023Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).Authorship 1073810337363962George S, Heinrich MC, Somaiah N, Oppelt P, McLeod R, Nishioka S, Kundu MG, Qian X, Kumar P, Laadem A, Lau Y, Tran BP, Fallon M, Dosunmu O, Shi J, Naito YClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor. Clin Cancer Res. 2023 09 15; 29(18):3659-3667.Clin Cancer Res2023-09-15T00:00:002023A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.Authorship 107717520Authorship 1079085337736254Gouda MA, Janku F, Somaiah N, Hunt KK, Yedururi S, Subbiah VOncoscienceMulti-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery. Oncoscience. 2023; 10:38-43.Oncoscience2023-09-20T00:00:002023Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.37598656Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S, INTRIGUE investigatorsEuropean journal of cancer (Oxford, England : 1990)Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer. 2023 10; 192:113245.Eur J Cancer2023-07-20T00:00:002023Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.Authorship 10810811237828359Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JCNature medicineRethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med. 2023 Nov; 29(11):2689-2692.Nat Med2023-11-01T00:00:002023Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.37914142Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJInternational journal of radiation oncology, biology, physicsSABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):971-978.Int J Radiat Oncol Biol Phys2023-10-30T00:00:002023SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.Authorship 108409431Authorship 1085036138104352Somaiah N, Tap WCancer treatment reviewsMDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev. 2024 Jan; 122:102668.Cancer Treat Rev2023-12-10T00:00:002023MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.Authorship 10863122138182785Heinrich MC, Jones RL, George S, Gelderblom H, Sch?ffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer SNature medicineRipretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30(2):498-506.Nat Med2024-01-05T00:00:002024Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.Authorship 10888615938351182Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah NNature cancerA randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Feb 13.Nat Cancer2024-02-13T00:00:002024A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.Authorship 1089898238405102Waguespack SG, Somaiah N, Lee JE, Elsayes KMJCEM case reportsIncomplete Carney Triad. JCEM Case Rep. 2024 Feb; 2(2):luae016.JCEM Case Rep2024-02-23T00:00:002024Incomplete Carney Triad.Authorship 10904672038473266Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah NCancersOutcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).Cancers (Basel)2024-02-23T00:00:002024Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professor24705628Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, Hoffman A, Pisters PW, Lev DC, Pollock REAnnals of surgical oncologyLocoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol. 2014 Jul; 21(7):2136-43.Ann Surg Oncol2014-04-07T00:00:002014Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?